Healio

Study investigates current status, unmet needs in DME management

A retrospective analysis of a large cohort of patients with diabetic macular edema showed high prevalence of bilateral ...
Ophthalmology Times

Anti-VEGF innovations in retinal disease: From molecules to medicine

Second-generation anti-VEGF agents, like aflibercept 8 mg and faricimab, show improved efficacy and treatment durability in ...
Nasdaq

ANI Pharmaceuticals Presents NEW DAY Trial Results: Evaluating ILUVIEN's Efficacy in Diabetic Macular Edema Treatment at ASRS Meeting

ANI Pharmaceuticals announced the results of the NEW DAY clinical trial for ILUVIEN® (fluocinolone acetonide) in diabetic macular edema (DME) patients during the ASRS Annual Scientific Meeting. The ...
KRON4 News

EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated ...